Sign in

You're signed outSign in or to get full access.

Brian Hughes

About Brian Hughes

Brian Hughes, age 66, is an independent Class II director of Resolute Holdings Management, Inc. (RHLD) and serves on the Audit Committee; he is designated as the Audit Committee Financial Expert. He has served on the RHLD Board since the February 28, 2025 spin-off completion. Hughes holds an MBA and a BS in Economics and Accounting from the Wharton School and has a CERT Certificate in Cybersecurity Oversight from Carnegie Mellon’s Software Engineering Institute .

Past Roles

OrganizationRoleTenureCommittees/Impact
KPMG LLPAudit Partner; National Private Markets Group Leader; Venture Capital Co-Leader2002–2019Senior leadership in audit and private markets; venture capital exposure
Arthur AndersenAudit Partner1981–2002Long-tenured audit and accounting leadership

External Roles

CompanyRoleCommittee PositionsNotes
Bentley Systems (Nasdaq: BSY)DirectorAudit Committee ChairPublic company board leadership and financial oversight
Innovid Corp. (NYSE: CTV)DirectorAudit Committee ChairAd tech and analytics governance; audit leadership
CompoSecure (Nasdaq: CMPO)DirectorAudit Committee MemberFintech/payments; multiple RHLD directors also serve on CMPO, indicating interlocks

Board Governance

AttributeDetail
IndependenceBoard affirmatively determined Hughes is independent under Nasdaq standards
Committee AssignmentsAudit Committee Member
Audit Committee Financial ExpertDesignated as “audit committee financial expert” under SEC rules
Classified BoardRHLD has a three-class staggered board; Hughes is Class II, term expiring at the 2026 annual meeting
Executive SessionsRHLD holds executive sessions of Board and committee meetings; no meetings occurred in FY2024 due to timing of spin-off
Controlled CompanyRHLD is a controlled company under Nasdaq rules; relies on certain governance exemptions
Hedging PolicyDirectors prohibited from hedging/shorting RHLD securities; policy covers options and similar instruments

Fixed Compensation

ComponentDetail
Director Compensation PolicyNon-employee directors receive stock options only (Initial Equity Award $50,000 grant-date value; Annual Equity Award $100,000 grant-date value). Both vest in equal annual installments over four years from grant anniversary; travel expenses reimbursed .
2025 Grants (Spin-Off Year)Effective Feb 28, 2025, non-employee directors, including Hughes, received an Initial Equity Award and a prorated Annual Equity Award totaling options for 2,064 shares at a $46.82 exercise price; four-year equal annual vesting .
Cash Fees at RHLDNot disclosed in RHLD’s 2025 proxy; compensation is weighted toward CMPO for overlapping directors .

Performance Compensation

Metric TypeStatus/Design
Performance-based Metrics (revenue, EBITDA, TSR, ESG)None disclosed for director compensation; RHLD director option awards vest time-based in equal annual installments over four years .

Other Directorships & Interlocks

Interlock AreaDetail
CMPO InterlocksMultiple RHLD directors serve on CompoSecure’s board (including Hughes); RHLD has a Management Agreement with CompoSecure Holdings with fees linked to Adjusted EBITDA, creating oversight interdependencies .
Audit Committee CompositionRHLD Audit Committee includes one non-independent member (Roger Fradin) under Nasdaq’s exceptional circumstances exception (max two years), alongside independent members including Hughes and DeAngelo (Chair) .

Expertise & Qualifications

  • Financial/accounting and audit expertise; designated Audit Committee Financial Expert .
  • Cybersecurity oversight credential (CERT); relevant to audit and risk oversight .
  • Extensive public company board experience and audit leadership at BSY and CTV .
  • Venture capital/private markets knowledge; deep audit background from KPMG and Arthur Andersen .

Equity Ownership

ItemAmountNotes
Common Shares Beneficially Owned7,858Less than 1% of 8,525,998 shares outstanding as of April 14, 2025 .
Options (2025 RHLD Director Grants)2,064 (unvested)Exercise price $46.82; equal annual vesting over four years; exercisable count not within 60 days of record date (unexercisable at grant) .
Pledging/HedgingHedging/shorting prohibited under Insider Trading Policy; pledging not specifically disclosed .

Governance Assessment

  • Independence and financial rigor: Hughes is independent and serves as RHLD’s Audit Committee Financial Expert, strengthening credibility of financial oversight and risk management .
  • Cross-board interlocks: Dual service on CMPO’s board amid RHLD’s Management Agreement and consolidated financial relationships with CompoSecure Holdings may create perceived conflicts in transaction review/oversight; appropriate mitigation is via RHLD’s Related Party Transaction policy and Audit Committee review .
  • Audit Committee composition risk: Presence of one non-independent member (Fradin) under Nasdaq’s “exceptional and limited circumstances” exception could raise investor scrutiny on audit independence, although constrained to a max of two years and justified by experience; Hughes’ expert role offsets some risk .
  • Director pay design: RHLD director pay is option-only with four-year time-based vesting and no disclosed cash retainers, which can align directors to equity value creation but lacks clear performance metrics; compensation is “weighted toward CompoSecure” for overlapping directors, potentially diluting RHLD-specific alignment .
  • Attendance data: Not available for FY2024 due to board timing; investors may look for FY2025 attendance disclosures in the 2026 proxy .

RED FLAGS

  • Audit Committee includes a non-independent member under an exception (max two years), elevating audit independence scrutiny despite Hughes’ financial expert designation .
  • Extensive interlocks with CompoSecure during and after spin-off, combined with a long-term Management Agreement and fee structure, increase related-party oversight demands .
Citations:
**[2039497_0001140361-25-014513_ny20045726x1_def14a.htm:12]** Director biography for Brian Hughes (age, roles, education, CERT cybersecurity credential)
**[2039497_0001140361-25-014513_ny20045726x1_def14a.htm:18]** Independence determinations
**[2039497_0001140361-25-014513_ny20045726x1_def14a.htm:19]** Committee memberships; board meeting disclosure for FY2024
**[2039497_0001140361-25-014513_ny20045726x1_def14a.htm:20]** Audit Committee composition; “audit committee financial expert” designation; Nasdaq exception details
**[2039497_0001140361-25-014513_ny20045726x1_def14a.htm:22]** Insider Trading Policy prohibitions (hedging/shorting)
**[2039497_0001140361-25-014513_ny20045726x1_def14a.htm:25]** Director compensation policy; 2025 option grants (2,064 shares; $46.82 strike; vesting schedule); compensation weighting comment
**[2039497_0001140361-25-014513_ny20045726x1_def14a.htm:23]** **[2039497_0001140361-25-014513_ny20045726x1_def14a.htm:24]** Beneficial ownership table (7,858 shares; <1%; shares outstanding)
**[2039497_0001140361-25-014513_ny20045726x1_def14a.htm:33]** Management Agreement with CompoSecure Holdings (fee structure, term)